Digital precision cancer medicine for discoveries and improved treatments
What is iCAN?

Breakthrough research for improved cancer diagnostics and treatments

iCAN aims to improve outcomes and quality of life of cancer patients. We do this through cutting-edge research focused on improving understanding in immuno-oncology, tumor microenvironment and development of disease resistance.
Our research projects leverage the iCAN discovery platform to identify new targets and solutions for diagnosing and treating cancer.

Integrating tumor molecular profiling and patients’ health data

The iCAN discovery platform links molecular profiling of tumors with broader health data of cancer patients, acting as a catalyst for breakthrough research and technologies.
The scale of data – 15,000 samples across different cancer types will be profiled by 2026 – enables real impact and broad studies across different cancer types. The platform will enable an improved understanding of the complex interplay between cancer cells and the host.

Accelerating world-class scientific innovation with the patient in focus

Our approach is to keep the patient in the focus in all activities in developing a research and innovation hub in digital precision cancer medicine.

At the center of the ecosystem is the iCAN discovery platform leveraged in collaborative partnerships among researchers and the life science industry.

Our latest news

iCAN - Digital Precision Cancer MedicineFollow559894

Connecting precision cancer medicine and digital health to create breakthrough discoveries. @SuomenAkatemia flagship, hosted by @helsinkiuni and @HUS_fi

iCAN - Digital Precision Cancer Medicine
iCAN is part of the Academy of Finland Flagship Programme and hosted by the University of Helsinki and HUS Helsinki University Hospital
Close Menu
AllEscort